CRNXCrinetics Pharmaceuticals Inc
CRNX
Crinetics Pharmaceuticals Inc1,455
Mkt Cap
$4.13BVolume
761,028.0052W High
$57.9952W Low
$25.83PE Ratio
-7.98CRNX Fundamentals
Price
$39.44Prev Close
$39.63Open
$39.6350D MA
$40.79Beta
1.19Avg. Volume
1.24MEPS (Annual)
-$4.95P/B
3.80Rev/Employee
$12,956.23$3,399.01
Jeff Knight Sells 85,163 Shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) insider Jeff Knight sold 85,163 shares of the company's stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $40.10, for a total transaction of $3,415,036.30. Following the completion of the sale...
MarketBeat·1d ago
Crinetics Pharmaceuticals (NASDAQ:CRNX) Insider Jeff Knight Sells 85,163 Shares
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) insider Jeff Knight sold 85,163 shares of the business's stock in a transaction that occurred on Wednesday, April 8th. The stock was...
MarketBeat·2d ago
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Acquired Rep. Gilbert Ray Cisneros, Jr.
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Crinetics Pharmaceuticals stock on March 3rd...
MarketBeat·3d ago
Aberdeen Group plc Buys 334,584 Shares of Crinetics Pharmaceuticals, Inc. $CRNX
Aberdeen Group plc lifted its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 98.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC...
MarketBeat·7d ago
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten analysts that are presently covering the stock, MarketBeat...
MarketBeat·14d ago
Crinetics Pharmaceuticals (NASDAQ:CRNX) Rating Lowered to "Sell" at Wall Street Zen
Wall Street Zen lowered Crinetics Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·15d ago
Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More
Key PointsA director of Crinetics Pharmaceuticals reported that he sold 5,000 shares of the company for a transaction value of approximately $180,761 on March 12, 2026...
Nasdaq News: Markets·16d ago
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 4.3% - Here's Why
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Down 4.3% - Time to Sell...
MarketBeat·20d ago
JPMorgan Chase & Co. Acquires 926,765 Shares of Crinetics Pharmaceuticals, Inc. $CRNX
JPMorgan Chase & Co. lifted its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 279.2% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 1,258,722 shares of the company's stock after acquiring an additional 926,765 share...
MarketBeat·22d ago
Richard Scott Struthers Sells 21,981 Shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) CEO Richard Scott Struthers sold 21,981 shares of the firm's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $37.37, for a total value of $821,429.97. Following the transaction, the chief...
MarketBeat·24d ago
<
1
2
...
>